Drug Name: 

SARILUMAB*

Drug Description: 
IL-6R Antibody
Target Condition: 
Noninfectious uveitis, juvenile idiopathic arthritis
Rank: 
20
Phase: 
Phase 2

NOW APPROVED IN THE UNITED STATES

Learn more